IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

ScinoPharm and Coland form alliance for oncological injectable products for China

1:41 AM MDT | May 14, 2013 | Deepti Ramesh

Active pharmaceutical ingredients (APIs) manufacturer ScinoPharm Taiwan (Shanhua, Taiwan) says that it has formed a strategic alliance with Coland Holdings (Shanghai) to develop a series of generic oncological drugs for mainland China. The cooperation utilizes ScinoPharm’s process R&D and production advantages in the field of highly potent oncological APIs and Coland’s well-established marketing capabilities in China to build an active presence within China’s rapidly growing anticancer drug market. Under the alliance, ScinoPharm will provide...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa